Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brigatinib

FDA-approved product (tablet, oral), marketed as Alunbrig.

Registered studies
48
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brigatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

48registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brigatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brigatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

    NCT04227028 · start 2020-03-09

    Registered record
    Registry ID
    NCT04227028
    Conditions
    Locally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Bevacizumab; Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2020-03-09
    Completion
    2027-03-25
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8 +6 more
    InterventionBevacizumab; Brigatinib
    PhasePhase 1
    Registry statusActive not recruiting

  • Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

    NCT04005144 · start 2020-02-25

    Registered record
    Registry ID
    NCT04005144
    Conditions
    ALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Progressive Disease; ROS1 Gene Rearrangement; Stage IIIB Lung Cancer; Stage IIIC Lung Cancer; Stage IV Lung Cancer; Stage IVA Lung Cancer; Stage IVB Lung Cancer
    Interventions
    Binimetinib; Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-02-25
    Completion
    2022-10-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Progressive Disease; ROS1 Gene Rearrangement +5 more
    InterventionBinimetinib; Brigatinib
    PhasePhase 1
    Registry statusTerminated

  • A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

    NCT04592523 · start 2019-09-05

    Registered record
    Registry ID
    NCT04592523
    Conditions
    Carcinoma, Non-Small-Cell Lung; Anaplastic Lymphoma Kinase
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-09-05
    Completion
    2026-03-12
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Anaplastic Lymphoma Kinase
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusCompleted

  • Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

    NCT03737994 · start 2019-07-25

    Registered record
    Registry ID
    NCT03737994
    Conditions
    Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Alectinib; Brigatinib; Carboplatin; Ceritinib; Cisplatin; Crizotinib; Ensartinib; Lorlatinib; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-07-25
    Completion
    2026-03-17
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    InterventionAlectinib; Brigatinib; Carboplatin; Ceritinib +5 more
    PhasePhase 2
    Registry statusTerminated

  • A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

    NCT03420742 · start 2019-06-26

    Registered record
    Registry ID
    NCT03420742
    Conditions
    Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
    Interventions
    Midazolam; Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-26
    Completion
    2021-04-29
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
    InterventionMidazolam; Brigatinib
    PhasePhase 1
    Registry statusCompleted

  • A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

    NCT03596866 · start 2019-04-19

    Registered record
    Registry ID
    NCT03596866
    Conditions
    ALK+ Advanced NSCLC
    Interventions
    Brigatinib; Alectinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-04-19
    Completion
    2024-09-18
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK+ Advanced NSCLC
    InterventionBrigatinib; Alectinib
    PhasePhase 3
    Registry statusCompleted

  • Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

    NCT03868423 · start 2019-03-20

    Registered record
    Registry ID
    NCT03868423
    Conditions
    Advanced Malignant Neoplasm; ALK Fusion Protein Expression; ALK Gene Amplification; ALK Gene Mutation; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Malignant Solid Neoplasm; ROS1 Fusion Positive; ROS1 Gene Amplification; ROS1 Gene Mutation
    Interventions
    Brigatinib; Laboratory Biomarker Analysis; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-03-20
    Completion
    2021-12-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Neoplasm; ALK Fusion Protein Expression; ALK Gene Amplification; ALK Gene Mutation +7 more
    InterventionBrigatinib; Laboratory Biomarker Analysis; Quality-of-Life Assessment; Questionnaire Administration
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

    NCT03535740 · start 2019-01-31

    Registered record
    Registry ID
    NCT03535740
    Conditions
    ALK-positive Advanced NSCLC
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-01-31
    Completion
    2024-08-21
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Advanced NSCLC
    InterventionBrigatinib
    PhasePhase 2
    Registry statusCompleted

  • Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

    NCT03707938 · start 2018-12-18

    Registered record
    Registry ID
    NCT03707938
    Conditions
    Advanced Lung Carcinoma; ALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Brigatinib; Local Consolidation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2018-12-18
    Completion
    2026-01-28
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lung Carcinoma; ALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma +3 more
    InterventionBrigatinib; Local Consolidation Therapy
    PhasePhase 1
    Registry statusActive not recruiting

  • Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

    NCT03719898 · start 2018-12-06

    Registered record
    Registry ID
    NCT03719898
    Conditions
    Anaplastic Large Cell Lymphoma, ALK-Positive
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2018-12-06
    Completion
    2020-06-16
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma, ALK-Positive
    InterventionBrigatinib
    PhasePhase 2
    Registry statusWithdrawn

  • A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

    NCT03546894 · start 2018-07-23

    Registered record
    Registry ID
    NCT03546894
    Conditions
    Anaplastic Lymphoma Kinase-positive; Carcinoma Non-small-cell Lung
    Interventions
    Brigatinib; Alectinib; Ceritinib; Lorlatinib; Any FDA Approved ALK Inhibitors
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-07-23
    Completion
    2023-02-13
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Lymphoma Kinase-positive; Carcinoma Non-small-cell Lung
    InterventionBrigatinib; Alectinib; Ceritinib; Lorlatinib +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases

    NCT03389399 · start 2018-02-22

    Registered record
    Registry ID
    NCT03389399
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-22
    Completion
    2021-10-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    NCT03410108 · start 2018-01-29

    Registered record
    Registry ID
    NCT03410108
    Conditions
    ALK-positive Advanced NSCLC
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-29
    Completion
    2021-07-28
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Advanced NSCLC
    InterventionBrigatinib
    PhasePhase 2
    Registry statusCompleted

  • Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

    NCT02706626 · start 2017-03-09

    Registered record
    Registry ID
    NCT02706626
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-03-09
    Completion
    2021-04-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    Interventionbrigatinib
    PhasePhase 2
    Registry statusTerminated

  • ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

    NCT02737501 · start 2016-05-26

    Registered record
    Registry ID
    NCT02737501
    Conditions
    Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
    Interventions
    Brigatinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05-26
    Completion
    2021-01-29
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
    InterventionBrigatinib; Crizotinib
    PhasePhase 3
    Registry statusCompleted